Anne-Renee Hartman

Co-founder and Chief Medical Officer

2020

Limited Partner

2019

Acting Chief Medical Officer, Vice President Clinical Development and Medical Affairs

2017 - 2019

Responsible for the design and implementation of the clinical development strategy to develop a cell-free nucleic acid multi-cancer early detection test. Built a team of over 60+ people and led them in creating and executing the largest clinical genomics program in medicine to develop a pan-cancer early detection blood test.

Medical Director

2016 - 2017

Advisor to Lewis Sigler Institute for Integrative Genomics

2017 - 2019

Senior Vice President, Clinical Development

2015 - 2016

VP, Clinical Development

2012 - 2015

• Responsible for leadership, development, approval and execution of the Clinical Validation Plans and Sample Procurement Plans for 5 products in the pipeline. Several of these products are launching in 2013. Report to Chief Medical Officer. • Led team that designed dozens of clinical trials for products in the pipeline from proof of concept to clinical validation. Products range from companion diagnostics to next-generation sequencing panels for risk assessment of cancer. Presenting abstracts at major meetings in 2014. • Championed development of proprietary Homologous Recombination Deficiency assay. Formed dozens of strategic collaborations for sample procurement and trial design. Procured ample resources for further development leading to successful proof of concept. • Performed initial diligence and led decision-making process on in-licensing opportunities in the Oncology space. Successfully identified and in-licensed several technologies • Responsible for the development and execution of 10+scientific advisory boards. • Effective collaborator with many cross functional groups including research, marketing, oncology business units and medical affairs and externally with strategic partners. Papers 2014: Nadine Tung MD, Chiara Battelli MD, Brian Allen MS,and Anne-Renee Hartman MD., Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel., Cancer, DOI: 10.1002/cncr.29010 Bueno, Raphael MD; Hughes, Elisha PhD, Hartman, Anne-Renee MD and Harrison, David J., Validation of a Molecular and Pathological Model for Five-Year Mortality Risk in Patients with Early Stage Lung Adenocarcinoma. Journal of Thoracic Oncology, doi: 10.1097/JTO.0365 David B. Zhen, Kari G. Rabe, Anne-Renee Hartman, Alison P. Klein, and Gloria M. Petersen., BRCA1, BRCA2, PALB2, and CDKN2A Mutations in Familial Pancreatic Cancer (FPC): A PACGENE Study.Genet Med 2014 Nov 6. Epub 2014 Nov 6.

Senior Medical Director

2011 - 2012

Hartman AR, Kaldate RR, Sailer LM, Painter L, Grier CE, Endsley RR, Griffin M, Hamilton SA, Frye CA, Silberman MA, Wenstrup RJ, Sandbach JF. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer. 2012 Jun 1;118(11):2787-95.

Consultant

2007 - 2010

Consultant

2006 - 2009

• Launched CYP2D6 testing for breast cancer patients considering adjuvant Tamoxifen therapy. • Developed content and physician letters for CYP2D6 testing service. • Developed and initiated clinical protocols evaluating CYP2D6 with major academic centers. • Edited and developed content for cancer genetic testing services. • Provided Strategic input on Business Development Projects in Cancer Diagnostics.

Assistant Professor of Medicine

2003 - 2005

Awards 2003 Mentored Patient-Oriented Research Career Development Award (K23), NIH 2003 Dunkin’ Donuts “Rising Stars” Award, Dana-Farber Cancer Institute 2004 Dunkin’ Donuts “Rising Stars” Award, Dana-Farber Cancer Institute 2005 Cancer Prevention Award, Dana Farber Cancer Institute PUBLICATIONS Kurian AW, Hartman AR, Mills MA, Ford JM, Daniel BL, Plevritis SK. Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: an initial evaluation from a screening trial including magnetic resonance imaging and ductal lavage. Health Expectations.2005;8:221-33. Kurian AW, Mills MA, Jaffee M, Sigal BM, Chun NM, Kingham KE, Collins LC, Nowels KW, Plevritis SK, Garber JE, Ford JM, Hartman AR. Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high inherited breast cancer risk. Cancer Epidemiology Biomarkers and Prevention 2005;14:1082-9. Chirnomas D, Taniguchi T, de la Vega M, Vaidya AP, Vasserman M, Hartman AR, Kennedy R, Foster R, Mahoney J, Seiden MV, D'Andrea ADChemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther. 2006 Apr;5(4):952-61. Ghanouni Pejman, Margolis Daniel, Kurian Allison, Hartman AR, Mills MA, Plevritis SK, Ford JM, Daniel Bruce. Ductal Enhancement on Magnetic Resonance Imaging of the Breast After Ductal Lavage. The Breast Journal. 2007;13:3:281-287 Proceedings of Meetings Hartman AR. The problems with risk selection; psychosocial and scientific aspects, St. Gallen controversies in tumor prevention and genetics. Proc Europ J Oncol, 2004. Reviews, Chapters, and Editorials Hartman AR. Familial breast and ovarian cancer: genetics, screening and management. N Engl J Med 2003; 349:2080-81. Garber JE, Hartman AR. Prophylactic oophorectomy and hormone replacement therapy: protection at what price? J Clin Oncol 2004; 22: 978-80.

Medical Oncology Fellowship

1998 - 2003

Selected Honors 2001 ASCO Young Investigator Award 2001 California Breast Cancer Research Program Postdoctoral Fellowship Award 2002 Susan Love M.D.BCRF Pilot Grant 2003 Department of Defense Breast Cancer Career Development Award 2003 Mentored Patient-Oriented Research Career Development Award (K23), NIH PUBLICATIONS Stucker D, Ikeda D, Hartman AR et al.,New bilateral microcalcifications at mammography in a postlactational woman: case report. Radiology 2000; 217: 247-50. Schor NF, Rudin C, Hartman AR et al., Cell line dependence of Bcl-2-induced alteration of glutathione handling. Oncogene 2000; 19: 472-6. Hartman AR, Dillon JJ, Fleming G. Meta-analysis of adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy in postmenopausal women with estrogen receptor-positive, node-positive breast cancer. Clin Breast Cancer 2001; 2: 138-143. Hartman AR, Ford JM. BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. Nature Genetics 2002; 32: 180-184. Hartman AR, Grekowicz A, Carlson RW et al., Phase I trial of uracil-ftorafur, leucovorin, and etoposide: an active all-oral regimen for metastatic breast cancer. Breast Cancer Res Treat 2003; 82:61-9. Hollingsworth AB et al., Current comprehensive assessment and management of women at increased risk for breast cancer. Am J Surg 2004; 187:349-62. Hartman AR, Daniel BL et al., Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma. Cancer 2004; 100:479-89. Kurian AW, Hartman AR et al., Magnetic resonance galactography: a feasibility study in women with prior atypical breast duct cytology., Breast J. 2008 Mar-Apr;14(2):211-4. Alli E, Sharma VB, Hartman AR et al., Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells. BMC Pharmacol. 2011 Jul 19;11:7. Reviews Hartman AR, Ford JM. BRCA1 and p53: compensatory roles in DNA repair. J Molec Med 2003; 81:700-7.